{"id":"eybelis-ophthalmic-solution-0-002","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Conjunctival hyperemia"},{"rate":"15-20","effect":"Corneal verticillata"},{"rate":"10-15","effect":"Conjunctival blanching"},{"rate":"10-15","effect":"Eye irritation"},{"rate":"5-10","effect":"Instillation site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rho kinase inhibitors work by blocking the Rho-associated coiled-coil containing protein kinase (ROCK), which leads to relaxation of the trabecular meshwork and Schlemm's canal, thereby improving aqueous humor drainage. This mechanism reduces intraocular pressure in glaucoma and ocular hypertension patients. Netarsudil, the active ingredient in Eybelis, is a selective ROCK inhibitor administered as a topical ophthalmic solution.","oneSentence":"Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:38.499Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT05279716","phase":"PHASE4","title":"Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl","status":"UNKNOWN","sponsor":"Santen Pharmaceutical Asia Pte. Ltd.","startDate":"2022-02-15","conditions":"Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omidenepag isopropyl ophthalmic solution"],"phase":"marketed","status":"active","brandName":"Eybelis ophthalmic solution 0.002%","genericName":"Eybelis ophthalmic solution 0.002%","companyName":"Santen Pharmaceutical Asia Pte. Ltd.","companyId":"santen-pharmaceutical-asia-pte-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}